



Clinical trial results:

A Phase 2 Open-Label Study in Infants with Respiratory Syncytial Virus Lower Respiratory Tract Infection, Followed by a Double-blind, Placebo Controlled Part, to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of RV521 (REVIRAL 1)

Summary

EudraCT number	2018-001010-15
Trial protocol	HU PL
Global end of trial date	05 December 2022

Results information

Result version number	v1 (current)
This version publication date	21 June 2023
First version publication date	21 June 2023

Trial information

Trial identification

Sponsor protocol code	C5241003
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04225897
WHO universal trial number (UTN)	-
Other trial identifiers	REVC003: Study ID

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 January 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 December 2022
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Part A and Part B: To evaluate the safety and tolerability of single (Part A) and multiple (Part B) oral doses of RV521 in infants hospitalised with Respiratory Syncytial Virus (RSV) lower respiratory tract infection (LRTI).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 November 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Hungary: 4
Country: Number of subjects enrolled	Malaysia: 7
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	Thailand: 9
Country: Number of subjects enrolled	Panama: 3
Country: Number of subjects enrolled	Spain: 27
Worldwide total number of subjects	51
EEA total number of subjects	31

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	43
Children (2-11 years)	8

Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was planned to be conducted in 3 parts: Part A, B and optional part C. Part C was not conducted as part of a reassessment of the clinical development plan for RV521 (sisunatovir); hence, data is not reported for Part C in any section of the results. A total of 51 subjects were enrolled in the study (Part A=19 and Part B=32).

Period 1

Period 1 title	Part A (Screening Visit to Day 7)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Cohort 1: RV521 1.0 mg/kg
------------------	---------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 1.0 milligram per kilogram (mg/kg) of RV521 orally on Day 1.

Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 1.0 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route on Day 1.

Arm title	Cohort 1: RV521 2.0 mg/kg
------------------	---------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.0 mg/kg of RV521 orally on Day 1.

Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 2.0 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route on Day 1.

Arm title	Cohort 1: RV521 2.5 mg/kg
------------------	---------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.5 mg/kg of RV521 orally on Day 1.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 2.5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route on Day 1.

Arm title	Cohort 2: RV521 2.0 mg/kg
------------------	---------------------------

Arm description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received a single dose of 2 mg/kg of RV521 orally on Day 1.

Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 2.0 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route on Day 1.

Number of subjects in period 1^[1]	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg
Started	3	7	3
Completed	3	6	1
Not completed	0	1	2
Adverse events	-	1	-
Parent/legal guardian request	-	-	1
Lost to follow-up	-	-	1

Number of subjects in period 1^[1]	Cohort 2: RV521 2.0 mg/kg
Started	6
Completed	6
Not completed	0
Adverse events	-
Parent/legal guardian request	-
Lost to follow-up	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Total 51 subjects were enrolled (Part A=19 and Part B=32).

Period 2

Period 2 title	Part B (Screening Visit to Day 12)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	No
Arm title	Cohort 3: Placebo

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received placebo every 12 hours twice daily (BID) orally for 5 days.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered placebo dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of placebo separated by 12 hours orally for 5 days.

Arm title	Cohort 3: RSV1 2.5 mg/kg
------------------	--------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 2.5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of RV521 separated by 12 hours orally for 5 days.

Arm title	Cohort 3: RV521 3.5 mg/kg
------------------	---------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 3.5 mg/kg every 12 hours (BID) orally for 5 days.

Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 3.5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of RV521 separated by 12 hours orally for 5 days.

Arm title	Cohort 3: RV521 5 mg/kg
------------------	-------------------------

Arm description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 5 mg/kg every 12 hours (BID) orally for 5 days.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered RV521 5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of RV521 separated by 12 hours orally for 5 days.	
Arm title	Cohort 4: Placebo
Arm description:	
Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered placebo dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of placebo separated by 12 hours orally for 5 days.	
Arm title	Cohort 4: RV521 2.5 mg/kg
Arm description:	
Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Arm type	Experimental
Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered RV521 2.5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of RV521 separated by 12 hours orally for 5 days.	
Arm title	Cohort 5: Placebo
Arm description:	
Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered placebo dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of placebo separated by 12 hours orally for 5 days.	
Arm title	Cohort 5: RV521 2.5 mg/kg
Arm description:	
Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Arm type	Experimental

Investigational medicinal product name	RV521
Investigational medicinal product code	
Other name	Sisunatovir
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered RV521 2.5 mg/kg dispersed in a defined volume of permitted suspending diluent via the oral route. Subjects received BID of RV521 separated by 12 hours orally for 5 days.

Number of subjects in period 2	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg
Started	3	3	4
Completed	3	3	4
Not completed	0	0	0
Parent/legal guardian request	-	-	-

Number of subjects in period 2	Cohort 3: RV521 5 mg/kg	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg
Started	3	1	4
Completed	2	1	4
Not completed	1	0	0
Parent/legal guardian request	1	-	-

Number of subjects in period 2	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Started	6	8
Completed	6	8
Not completed	0	0
Parent/legal guardian request	-	-

Baseline characteristics

Reporting groups

Reporting group title	Cohort 1: RV521 1.0 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 1.0 milligram per kilogram (mg/kg) of RV521 orally on Day 1.	
Reporting group title	Cohort 1: RV521 2.0 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.0 mg/kg of RV521 orally on Day 1.	
Reporting group title	Cohort 1: RV521 2.5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.5 mg/kg of RV521 orally on Day 1.	
Reporting group title	Cohort 2: RV521 2.0 mg/kg
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received a single dose of 2 mg/kg of RV521 orally on Day 1.	

Reporting group values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg
Number of subjects	3	7	3
Age Categorical			
Units: Subjects			
Infants and toddlers (28 days-23 months)	1	5	3
Children (2-11 years)	2	2	0
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months			
arithmetic mean	27.8	18.1	9.4
standard deviation	± 5.90	± 7.25	± 2.46
Gender Categorical			
Units: Subjects			
Female	0	4	2
Male	3	3	1
Race			
Units: Subjects			
American Indian or Alaskan Native	0	0	0
Asian	0	7	0
White	3	0	3
Black or African American	0	0	0
Unknown or Other	0	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	3
Not Hispanic or Latino	3	7	0
Unknown	0	0	0

Reporting group values	Cohort 2: RV521 2.0 mg/kg	Total	
------------------------	---------------------------	-------	--

Number of subjects	6	19	
Age Categorical			
Units: Subjects			
Infants and toddlers (28 days-23 months)	6	15	
Children (2-11 years)	0	4	
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months			
arithmetic mean	2.7		
standard deviation	± 1.69	-	
Gender Categorical			
Units: Subjects			
Female	1	7	
Male	5	12	
Race			
Units: Subjects			
American Indian or Alaskan Native	1	1	
Asian	1	8	
White	4	10	
Black or African American	0	0	
Unknown or Other	0	0	
Ethnicity			
Units: Subjects			
Hispanic or Latino	1	4	
Not Hispanic or Latino	5	15	
Unknown	0	0	

Subject analysis sets

Subject analysis set title	Cohort 3: Placebo
Subject analysis set type	Safety analysis
Subject analysis set description:	
Infants aged ≥6 months to ≤36 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Subject analysis set title	Cohort 3: RSV1 2.5 mg/kg
Subject analysis set type	Safety analysis
Subject analysis set description:	
Infants aged ≥6 months to ≤36 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Subject analysis set title	Cohort 3: RV521 3.5 mg/kg
Subject analysis set type	Safety analysis
Subject analysis set description:	
Infants aged ≥6 months to ≤36 months hospitalised with RSV LRTI received RV521 3.5 mg/kg every 12 hours (BID) orally for 5 days.	
Subject analysis set title	Cohort 3: RV521 5 mg/kg
Subject analysis set type	Safety analysis
Subject analysis set description:	
Infants aged ≥6 months to ≤36 months hospitalised with RSV LRTI received RV521 5 mg/kg every 12 hours (BID) orally for 5 days.	
Subject analysis set title	Cohort 4: Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 4: RV521 2.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 5: Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 5: RV521 2.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 4 and 5 combined: RV521 2.5 mg/kg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received BID of RV521 2.5 mg/kg separated by 12 hours orally for 5 days. Subjects from Cohort 4 and 5 were included.

Subject analysis set title	Cohort 4 and 5 combined: Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received BID of placebo separated by 12 hours orally for 5 days. Subjects from Cohorts 4 and 5 were included.

Reporting group values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg
Number of subjects	3	3	4
Age Categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	3	3	2
Children (2-11 years)	0	0	2
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months arithmetic mean standard deviation	17.5 ± 4.00	8.9 ± 4.51	18.5 ± 13.54
Gender Categorical Units: Subjects			
Female	1	1	3
Male	2	2	1
Race Units: Subjects			
American Indian or Alaskan Native	1	0	0
Asian	1	3	1
White	1	0	3
Black or African American	0	0	0
Unknown or Other	0	0	0
Ethnicity			

Units: Subjects			
Hispanic or Latino	1	0	0
Not Hispanic or Latino	2	3	4
Unknown	0	0	0

Reporting group values	Cohort 3: RV521 5 mg/kg	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg
Number of subjects	3	1	4
Age Categorical			
Units: Subjects			
Infants and toddlers (28 days-23 months)	1	1	4
Children (2-11 years)	2	0	0
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months			
arithmetic mean	22.2	1.6	1.2
standard deviation	± 7.97	± 99999	± 0.43
Gender Categorical			
Units: Subjects			
Female	2	0	0
Male	1	1	4
Race			
Units: Subjects			
American Indian or Alaskan Native	0	0	0
Asian	1	0	0
White	1	1	4
Black or African American	0	0	0
Unknown or Other	1	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	3	1	3
Unknown	0	0	0

Reporting group values	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg	Cohort 4 and 5 combined: RV521 2.5 mg/kg
Number of subjects	5	8	12
Age Categorical			
Units: Subjects			
Infants and toddlers (28 days-23 months)	5	8	12
Children (2-11 years)	0	0	0
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months			
arithmetic mean	2.0	3.0	2.4
standard deviation	± 0.47	± 1.10	± 1.26
Gender Categorical			
Units: Subjects			
Female	0	5	5
Male	5	3	7

Race			
Units: Subjects			
American Indian or Alaskan Native	0	1	1
Asian	1	1	1
White	2	6	10
Black or African American	1	0	0
Unknown or Other	1	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	2	1	2
Not Hispanic or Latino	2	7	10
Unknown	1	0	0

Reporting group values	Cohort 4 and 5 combined: Placebo		
Number of subjects	6		
Age Categorical			
Units: Subjects			
Infants and toddlers (28 days-23 months)	6		
Children (2-11 years)	0		
Age Continuous			
99999 indicates standard deviation could not be calculated as a single subject was analysed.			
Units: months			
arithmetic mean	1.9		
standard deviation	± 0.45		
Gender Categorical			
Units: Subjects			
Female	0		
Male	6		
Race			
Units: Subjects			
American Indian or Alaskan Native	0		
Asian	1		
White	3		
Black or African American	1		
Unknown or Other	1		
Ethnicity			
Units: Subjects			
Hispanic or Latino	2		
Not Hispanic or Latino	3		
Unknown	1		

End points

End points reporting groups

Reporting group title	Cohort 1: RV521 1.0 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 1.0 milligram per kilogram (mg/kg) of RV521 orally on Day 1.	
Reporting group title	Cohort 1: RV521 2.0 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.0 mg/kg of RV521 orally on Day 1.	
Reporting group title	Cohort 1: RV521 2.5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.5 mg/kg of RV521 orally on Day 1.	
Reporting group title	Cohort 2: RV521 2.0 mg/kg
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received a single dose of 2 mg/kg of RV521 orally on Day 1.	
Reporting group title	Cohort 3: Placebo
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received placebo every 12 hours twice daily (BID) orally for 5 days.	
Reporting group title	Cohort 3: RSV1 2.5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 3: RV521 3.5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 3.5 mg/kg every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 3: RV521 5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 5 mg/kg every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 4: Placebo
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 4: RV521 2.5 mg/kg
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 5: Placebo
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 5: RV521 2.5 mg/kg
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	
Subject analysis set title	Cohort 3: Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 3: RSV1 2.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 3: RV521 3.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 3.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 3: RV521 5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 4: Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 4: RV521 2.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 5: Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 5: RV521 2.5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Subject analysis set title	Cohort 4 and 5 combined: RV521 2.5 mg/kg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received BID of RV521 2.5 mg/kg separated by 12 hours orally for 5 days. Subjects from Cohort 4 and 5 were included.

Subject analysis set title	Cohort 4 and 5 combined: Placebo
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received BID of placebo separated by 12 hours orally for 5 days. Subjects from Cohorts 4 and 5 were included.

Primary: Part A: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Withdrawals due to TEAEs

End point title	Part A: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Withdrawals due to TEAEs ^[1]
-----------------	--

End point description:

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study subject

administered a medicinal product which did not necessarily have a causal relationship with the investigational medicinal product (IMP). TEAEs were defined as AEs which started, or worsened, after the first dose of IMP. An SAE was any untoward medical occurrence or effect that, at any dose, resulted in death; was life threatening; required or prolonged inpatient hospitalisation; resulted in persistent or significant disability/incapacity or other important medical event. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

From start of IMP on Day 1 up to Day 7

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects				
TEAEs	2	5	3	1
SAEs	0	1	0	0
Withdrawals due to TEAEs	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Withdrawals due to TEAEs

End point title	Part B: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Withdrawals due to TEAEs ^[2]
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which did not necessarily have a causal relationship with the IMP. TEAEs were defined as AEs which started, or worsened, after the first dose of IMP. An SAE was any untoward medical occurrence or effect that, at any dose, resulted in death; was life threatening; required or prolonged inpatient hospitalisation; resulted in persistent or significant disability/incapacity or other important medical event. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

From start of IMP on Day 1 up to Day 12

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects				
TEAEs	1	2	1	1
SAEs	0	0	0	0
Withdrawal due to TEAEs	0	0	0	1

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects				
TEAEs	1	2	3	1
SAEs	0	0	0	0
Withdrawal due to TEAEs	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Physical Examination Results at Baseline

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Physical Examination Results at Baseline ^[3]
-----------------	---

End point description:

Physical examination included general appearance; head, eyes, ears, nose and throat (HEENT); dermatologic; cardiovascular; respiratory; gastrointestinal; and neurological examination. Clinical significance of results were determined by the investigator. Safety population included all subjects who received at least 1 dose of IMP. Here, 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects				
General appearance; n=3,7,3,5	0	1	0	0
HEENT; n=3,7,3,4	1	2	0	0

Dermatologic; n=3,7,3,4	0	0	0	0
Cardiovascular; n=3,7,3,5	0	1	0	0
Respiratory; n=3,7,3,5	3	6	2	1
Gastrointestinal; n=3,7,3,5	0	0	0	0
Neurological; n=3,7,3,5	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Physical Examination Results Anytime Between 18 to 24 Hours Post-dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Physical Examination Results Anytime Between 18 to 24 Hours Post-dose ^[4]
-----------------	--

End point description:

Physical examination included general appearance; HEENT; dermatologic; cardiovascular; respiratory; gastrointestinal; and neurological examination. Clinical significance of results were determined by the investigator. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 18 to 24 hours post-dose on Day 1

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects				
General appearance; n=3,6,2,6	0	0	0	0
HEENT; n=3,6,1,5	1	2	0	0
Dermatologic; n=3,6,1,5	0	0	0	0
Cardiovascular; n=3,6,2,6	0	0	0	0
Respiratory; n=3,6,2,6	1	4	1	1
Gastrointestinal; n=3,6,2,6	0	0	0	0
Neurological; n=3,6,2,6	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Physical Examination Results at 48 Hours Post-dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant
-----------------	---

End point description:

Physical examination included general appearance; HEENT; dermatologic; cardiovascular; respiratory; gastrointestinal; and neurological examination. Clinical significance of results were determined by the investigator. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

At 48 hours post-dose on Day 1

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects				
General appearance; n=3,6,2,6	0	0	0	0
HEENT; n=3,6,2,5	1	1	1	0
Dermatologic; n=3,6,2,5	0	0	0	0
Cardiovascular; n=3,6,2,6	0	0	0	0
Respiratory; n=3,6,2,6	1	3	1	1
Gastrointestinal; n=3,6,2,6	0	0	0	0
Neurological; n=3,6,2,6	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Physical Examination Results at Baseline

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Physical Examination Results at Baseline ^[6]
-----------------	---

End point description:

Physical examination included general appearance; dermatologic; cardiovascular; respiratory; gastrointestinal; and neurological examination. Clinical significance of results were determined by the investigator. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	4	3
Units: Subjects				
General Appearance; n=2,3,4,3,1,4,5,7	0	0	1	0
HEENT; n=2,3,3,3,1,4,5,7	0	0	1	1
Dermatologic; n=2,3,4,3,1,4,5,7	0	0	0	0
Cardiovascular; n=2,3,4,3,1,4,5,7	0	0	1	0
Respiratory; n=2,3,4,3,1,4,5,7	1	2	3	3
Gastrointestinal; n=2,3,4,3,1,4,5,7	0	0	0	0
Neurological; n=2,3,4,3,1,4,5,7	0	0	1	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	7
Units: Subjects				
General Appearance; n=2,3,4,3,1,4,5,7	0	0	0	1
HEENT; n=2,3,3,3,1,4,5,7	0	0	0	0
Dermatologic; n=2,3,4,3,1,4,5,7	0	0	0	0
Cardiovascular; n=2,3,4,3,1,4,5,7	0	0	0	0
Respiratory; n=2,3,4,3,1,4,5,7	1	2	4	3
Gastrointestinal; n=2,3,4,3,1,4,5,7	0	0	0	0
Neurological; n=2,3,4,3,1,4,5,7	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Physical Examination Results Anytime Between 40 to 48 Hours Post-dose 10

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Physical Examination Results Anytime Between 40 to 48 Hours Post-dose 10 ^[7]
-----------------	---

End point description:

Physical examination included general appearance; HEENT; dermatologic; cardiovascular; respiratory; gastrointestinal; and neurological examination. Clinical significance of results were determined by the investigator. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects				
General appearance; n=3,3,4,2,0,4,5,8	0	0	0	0
HEENT; n=3,3,3,2,0,4,5,8	0	0	1	0
Dermatologic; n=3,3,3,2,0,4,5,8	0	0	0	0
Cardiovascular; n=3,3,3,2,0,4,5,8	0	0	0	0
Respiratory; n=3,3,4,2,0,4,5,8	0	1	0	0
Gastrointestinal; n=3,3,3,2,0,4,5,8	0	0	0	0
Neurological; n=3,3,3,2,0,4,5,8	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[8]	4	5	8
Units: Subjects				
General appearance; n=3,3,4,2,0,4,5,8		0	0	0
HEENT; n=3,3,3,2,0,4,5,8		0	0	0
Dermatologic; n=3,3,3,2,0,4,5,8		0	0	0
Cardiovascular; n=3,3,3,2,0,4,5,8		0	0	0
Respiratory; n=3,3,4,2,0,4,5,8		1	0	0
Gastrointestinal; n=3,3,3,2,0,4,5,8		0	0	0
Neurological; n=3,3,3,2,0,4,5,8		0	0	0

Notes:

[8] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Baseline

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Baseline ^[9]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects	0	2	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose ^[10]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose on Day 1

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects	0	1	1	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at 12 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at 12 Hours Post-Dose ^[11]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

12 hours post-dose on Day 1

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	2	6
Units: Subjects	0	2	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 18 to 24 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 18 to 24 Hours Post-Dose ^[12]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 18 to 24 hours post-dose on Day 1

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects	0	2	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at 48 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

48 hours post-dose on Day 1

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects	0	1	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Vital Signs per Investigator's Interpretation at Baseline

End point title	Part B: Number of Subjects With Abnormal Vital Signs per Investigator's Interpretation at Baseline ^[14]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 1

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 1 ^[15]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose 1 (Day 1)

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects	1	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs

per Investigator's Interpretation At Pre-dose 2

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation At Pre-dose 2 ^[16]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 2 (Day 1)

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	1	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 3

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 3 ^[17]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 3 (Day 2)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 4

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 4 ^[18]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 4 (Day 2)

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	1	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 5

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 5 ^[19]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 5 (Day 3)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	1	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs

per Investigator's Interpretation at Pre-dose 6

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 6 ^[20]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 6 (Day 3)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	4	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 6

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 6 ^[21]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose 6 (Day 3)

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	4	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 7

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 7 ^[22]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 7 (Day 4)

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	1	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 8

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 8 ^[23]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 8 (Day 4)

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	2	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	4	6
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs

per Investigator's Interpretation at Pre-dose 9

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 9 ^[24]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 9 (Day 5)

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	2	1
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	4	5
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 10

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation at Pre-dose 10 ^[25]
-----------------	--

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 10 (Day 5)

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	1	1
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	4	4
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 40 to 48 Hours Post-Dose 10

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Vital Signs per Investigator's Interpretation Anytime Between 40 to 48 Hours Post-Dose 10 ^[26]
-----------------	---

End point description:

Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate, heart rate and pulse oximetry. Number of subjects with abnormal clinically significant vital signs per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[27]	4	5	8
Units: Subjects		0	0	0

Notes:

[27] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Hematology Results at Baseline

End point title	Part A: Number of Subjects With Abnormal Hematology Results at Baseline ^[28]
-----------------	---

End point description:

Haematology parameters included basophils, eosinophils, lymphocytes, monocytes, neutrophils, haemoglobin (Hb), haematocrit (HCT), white blood cell count (WBC), red blood cell count (RBC), platelet count, mean cell volume (MCV), mean cell haemoglobin (MCH), and MCH concentration (MCHC). Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	7	3	6
Units: Subjects				
Basophils; below normal range; n=2,7,1,6	0	0	0	0
Basophils; above normal range; n=2,7,1,6	0	0	0	0
Eosinophils; below normal range; n=2,7,1,6	0	0	0	0
Eosinophils; above normal range; n=2,7,1,6	0	0	0	0
MCHC; below normal range; n=2,7,1,6	0	0	0	0
MCHC; above normal range; n=2,7,1,6	0	0	0	0
MCH; below normal range; n=2,7,1,6	0	0	0	0
MCH; above normal range; n=2,7,1,6	0	0	0	0
MCV; below normal range; n=2,7,1,6	0	0	0	0
MCV; above normal range; n=2,7,1,6	0	0	0	0
RBC; below normal range; n=2,7,1,6	0	0	0	0

RBC; above normal range; n=2,7,1,6	0	0	0	0
HCT; below normal range; n=2,7,1,6	0	0	0	0
HCT; above normal range; n=2,7,1,6	0	0	0	0
Hb; below normal range; n=2,7,3,6	0	0	1	0
Hb; above normal range; n=2,7,3,6	0	0	0	0
WBC; below normal range; n=2,7,1,6	0	0	1	1
WBC; above normal range; n=2,7,1,6	0	0	0	0
Lymphocytes; below normal range; n=2,7,1,6	0	0	0	0
Lymphocytes; above normal range; n=2,7,1,6	0	0	0	0
Monocytes; below normal range; n=2,7,1,6	0	0	0	0
Monocytes; above normal range; n=2,7,1,6	0	0	0	0
Neutrophils; below normal range; n=2,7,1,6	0	0	0	0
Neutrophils; above normal range; n=2,7,1,6	0	0	0	0
Platelets; below normal range; n=2,7,1,6	0	2	0	1
Platelets; above normal range; n=2,7,1,6	0	0	0	1

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Hematology Results at 48 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Hematology Results at 48 Hours Post-Dose ^[29]
-----------------	---

End point description:

Haematology parameters included basophils, eosinophils, lymphocytes, monocytes, neutrophils, Hb, HCT, WBC, RBC, platelet count, MCV, MCH and MCHC. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

48 hours post-dose on Day 1

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	5
Units: Subjects				
Basophils; below normal range; n=3,6,1,5	0	0	0	0

Basophils; above normal range; n=3,6,1,5	0	0	0	0
Eosinophils; below normal range; n=3,6,1,5	0	0	0	0
Eosinophils; above normal range; n=3,6,1,5	0	0	0	0
MCHC; below normal range; n=3,6,1,5	0	0	0	0
MCHC; above normal range; n=3,6,1,5	0	0	0	0
MCH; below normal range; n=3,6,1,5	0	0	0	0
MCH; above normal range; n=3,6,1,5	0	0	0	0
MCV; below normal range; n=3,6,1,5	0	0	0	0
MCV; above normal range; n=3,6,1,5	0	0	0	0
RBC; below normal range; n=3,6,1,5	0	0	0	0
RBC; above normal range; n=3,6,1,5	0	0	0	0
HCT; below normal range; n=3,6,1,5	0	0	0	0
HCT; above normal range; n=3,6,1,5	0	0	0	0
Hb; below normal range; n=3,6,2,5	0	0	0	0
Hb; above normal range; n=3,6,2,5	0	0	0	0
WBC; below normal range; n=3,6,1,5	0	0	0	0
WBC; above normal range; n=3,6,1,5	0	0	0	1
Lymphocytes; below normal range; n=3,6,1,5	0	0	0	0
Lymphocytes; above normal range; n=3,6,1,5	0	0	0	0
Monocytes; below normal range; n=3,6,1,5	0	0	0	0
Monocytes; above normal range; n=3,6,1,5	0	0	0	0
Neutrophils; below normal range; n=3,6,1,5	0	0	0	0
Neutrophils; above normal range; n=3,6,1,5	0	0	0	0
Platelets; below normal range; n=3,6,1,5	0	1	0	0
Platelets; above normal range; n=3,6,1,5	1	1	1	1

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Hematology Results at Baseline

End point title	Part B: Number of Subjects With Abnormal Hematology Results at Baseline ^[30]
-----------------	---

End point description:

Haematology parameters included basophils, eosinophils, lymphocytes, monocytes, neutrophils, Hb, HCT, WBC, RBC, platelet count, MCV, MCH and MCHC. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	1
Units: Subjects				
Basophils; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Basophils; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Eosinophils; below normal range; n=3,3,3,1,0,4,2,7	1	0	1	0
Eosinophils; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
MCHC; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
MCHC; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
MCH; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
MCH; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
MCV; below normal range; n=3,3,3,1,0,4,2,7	0	0	1	0
MCV; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
RBC; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
RBC; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
HCT; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	1
HCT; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Hb; below normal range; n=3,3,3,1,0,4,2,7	0	0	1	0
Hb; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
WBC; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
WBC; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Lymphocytes; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Lymphocytes; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Monocytes; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Monocytes; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Neutrophils; below normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Neutrophils; above normal range; n=3,3,3,1,0,4,2,7	0	0	0	0
Platelets; below normal range; n=3,3,3,1,0,3,2,7	1	0	1	0

Platelets; above normal range; n=3,3,3,1,0,3,2,7	1	0	0	0
---	---	---	---	---

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[31]	4	2	7
Units: Subjects				
Basophils; below normal range; n=3,3,3,1,0,4,2,7		0	0	0
Basophils; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
Eosinophils; below normal range; n=3,3,3,1,0,4,2,7		0	0	2
Eosinophils; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
MCHC; below normal range; n=3,3,3,1,0,4,2,7		0	0	1
MCHC; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
MCH; below normal range; n=3,3,3,1,0,4,2,7		0	0	1
MCH; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
MCV; below normal range; n=3,3,3,1,0,4,2,7		0	0	0
MCV; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
RBC; below normal range; n=3,3,3,1,0,4,2,7		0	0	0
RBC; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
HCT; below normal range; n=3,3,3,1,0,4,2,7		0	2	0
HCT; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
Hb; below normal range; n=3,3,3,1,0,4,2,7		0	1	1
Hb; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
WBC; below normal range; n=3,3,3,1,0,4,2,7		2	1	0
WBC; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
Lymphocytes; below normal range; n=3,3,3,1,0,4,2,7		0	1	0
Lymphocytes; above normal range; n=3,3,3,1,0,4,2,7		0	0	0
Monocytes; below normal range; n=3,3,3,1,0,4,2,7		0	0	1
Monocytes; above normal range; n=3,3,3,1,0,4,2,7		0	1	1
Neutrophils; below normal range; n=3,3,3,1,0,4,2,7		0	0	0
Neutrophils; above normal range; n=3,3,3,1,0,4,2,7		0	0	0

Platelets; below normal range; n=3,3,3,1,0,3,2,7		0	0	0
Platelets; above normal range; n=3,3,3,1,0,3,2,7		0	0	1

Notes:

[31] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Hematology Results Anytime Between 40 to 48 Hours Post-dose 10

End point title	Part B: Number of Subjects With Abnormal Hematology Results Anytime Between 40 to 48 Hours Post-dose 10 ^[32]
-----------------	---

End point description:

Haematology parameters included basophils, eosinophils, lymphocytes, monocytes, neutrophils, Hb, HCT, WBC, RBC, platelet count, MCV, MCH and MCHC. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	4	2
Units: Subjects				
Basophils; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Basophils; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Eosinophils; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Eosinophils; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
MCHC; below normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
MCHC; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	1
MCH; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	1
MCH; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
MCV; below normal range; n=3,2,4,2,0,1,3,7	0	0	1	1
MCV; above normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
RBC; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0

RBC; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
HCT; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
HCT; above normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
Hb; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Hb; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
WBC; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
WBC; above normal range; n=3,2,4,2,0,1,3,7	1	0	0	0
Lymphocytes; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Lymphocytes; above normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Monocytes; below normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
Monocytes; above normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
Neutrophils; below normal range; n=3,2,4,2,0,1,3,7	0	0	0	0
Neutrophils; above normal range; n=3,2,4,2,0,1,3,7	0	0	1	0
Platelets; below normal range; n=3,2,3,1,0,1,3,7	0	0	0	0
Platelets; above normal range; n=3,2,3,1,0,1,3,7	2	1	2	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[33]	1	3	7
Units: Subjects				
Basophils; below normal range; n=3,2,4,2,0,1,3,7		0	0	0
Basophils; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
Eosinophils; below normal range; n=3,2,4,2,0,1,3,7		0	0	0
Eosinophils; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
MCHC; below normal range; n=3,2,4,2,0,1,3,7		0	1	1
MCHC; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
MCH; below normal range; n=3,2,4,2,0,1,3,7		0	0	1
MCH; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
MCV; below normal range; n=3,2,4,2,0,1,3,7		0	0	0
MCV; above normal range; n=3,2,4,2,0,1,3,7		0	1	0

RBC; below normal range; n=3,2,4,2,0,1,3,7		0	0	0
RBC; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
HCT; below normal range; n=3,2,4,2,0,1,3,7		0	2	0
HCT; above normal range; n=3,2,4,2,0,1,3,7		0	1	0
Hb; below normal range; n=3,2,4,2,0,1,3,7		0	0	1
Hb; above normal range; n=3,2,4,2,0,1,3,7		0	1	0
WBC; below normal range; n=3,2,4,2,0,1,3,7		0	1	1
WBC; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
Lymphocytes; below normal range; n=3,2,4,2,0,1,3,7		0	0	1
Lymphocytes; above normal range; n=3,2,4,2,0,1,3,7		0	0	0
Monocytes; below normal range; n=3,2,4,2,0,1,3,7		0	1	1
Monocytes; above normal range; n=3,2,4,2,0,1,3,7		0	1	1
Neutrophils; below normal range; n=3,2,4,2,0,1,3,7		0	1	1
Neutrophils; above normal range; n=3,2,4,2,0,1,3,7		0	1	0
Platelets; below normal range; n=3,2,3,1,0,1,3,7		0	0	0
Platelets; above normal range; n=3,2,3,1,0,1,3,7		0	2	6

Notes:

[33] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinical Chemistry Results at Baseline

End point title	Part A: Number of Subjects With Abnormal Clinical Chemistry Results at Baseline ^[34]
-----------------	---

End point description:

Clinical chemistry parameters included creatinine, urea (or blood urea nitrogen), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total bilirubin, albumin, total protein, sodium, potassium, chloride, glucose, and calcium. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects				
ALT; below normal range; n=3,7,3,5	0	0	0	0
ALT; above normal range; n=3,7,3,5	0	0	0	0
Albumin; below normal range; n=3,7,3,6	0	0	0	0
Albumin; above normal range; n=3,7,3,6	0	0	0	0
ALP; below normal range; n=3,7,3,5	0	0	0	0
ALP; above normal range; n=3,7,3,5	0	0	0	0
AST; below normal range; n=3,7,3,5	0	0	0	0
AST; above normal range; n=3,7,3,5	0	0	0	0
Bilirubin; below normal range; n=3,7,3,6	0	0	0	0
Bilirubin; above normal range; n=3,7,3,6	0	0	0	0
Calcium; below normal range; n=3,7,3,6	0	1	0	0
Calcium; above normal range; n=3,7,3,6	0	0	0	1
Chloride; below normal range; n=3,7,3,6	0	0	0	0
Chloride; above normal range; n=3,7,3,6	0	0	0	0
Creatinine; below normal range; n=3,7,3,6	0	0	0	0
Creatinine; above normal range; n=3,7,3,6	0	0	0	0
GGT; below normal range; n=3,7,3,5	0	0	0	0
GGT; above normal range; n=3,7,3,5	0	0	0	0
Glucose; below normal range; n=3,7,3,6	0	0	0	0
Glucose; above normal range; n=3,7,3,6	0	0	0	0
LDH; below normal range; n=3,7,3,3	0	0	0	0
LDH; above normal range; n=3,7,3,3	0	0	0	0
Potassium; below normal range; n=3,7,3,4	0	0	0	0
Potassium; above normal range; n=3,7,3,4	0	0	0	1
Protein; below normal range; n=3,7,3,6	0	0	0	0
Protein; above normal range; n=3,7,3,6	0	0	0	0
Sodium; below normal range; n=3,7,3,6	0	1	0	0
Sodium; above normal range; n=3,7,3,6	0	0	0	0
Urea; below normal range; n=3,7,3,6	0	0	0	0
Urea; above normal range; n=3,7,3,6	0	0	0	0

Statistical analyses

Primary: Part A: Number of Subjects With Abnormal Clinical Chemistry Results at 48 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinical Chemistry Results at 48 Hours Post-Dose ^[35]
-----------------	---

End point description:

Clinical chemistry parameters included creatinine, urea, AST, ALT, GGT, ALP, LDH, total bilirubin, albumin, total protein, sodium, potassium, chloride, glucose, and calcium. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

48 hours post-dose on Day 1

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects				
ALT; below normal range; n=3,6,1,5	0	0	0	0
ALT; above normal range; n=3,6,1,5	0	0	0	0
Albumin; below normal range; n=3,6,1,5	0	0	0	0
Albumin; above normal range; n=3,6,1,5	0	0	0	0
ALP; below normal range; n=3,6,1,5	0	0	0	0
ALP; above normal range; n=3,6,1,5	0	0	0	0
AST; below normal range; n=3,5,1,5	0	0	0	0
AST; above normal range; n=3,5,1,5	0	0	0	0
Bilirubin; below normal range; n=3,6,1,5	0	0	0	0
Bilirubin; above normal range; n=3,6,1,5	0	0	0	0
Calcium; below normal range; n=3,6,1,5	0	0	0	0
Calcium; above normal range; n=3,6,1,5	0	0	0	1
Chloride; below normal range; n=3,6,1,5	0	0	0	0
Chloride; above normal range; n=3,6,1,5	0	0	0	0
Creatinine; below normal range; n=3,6,1,4	0	0	0	0
Creatinine; above normal range; n=3,6,1,4	0	0	0	0
GGT; below normal range; n=3,6,1,5	0	0	0	0
GGT; above normal range; n=3,6,1,5	0	0	0	0
Glucose; below normal range; n=3,6,1,4	0	0	0	1
Glucose; above normal range; n=3,6,1,4	0	0	0	0

LDH; below normal range; n=3,5,1,5	0	0	0	0
LDH; above normal range; n=3,5,1,5	0	0	0	0
Potassium; below normal range; n=3,5,1,4	0	0	0	0
Potassium; above normal range; n=3,5,1,4	0	1	0	3
Protein; below normal range; n=3,6,1,5	0	0	0	0
Protein; above normal range; n=3,6,1,5	0	0	0	0
Sodium; below normal range; n=3,6,1,5	0	0	0	0
Sodium; above normal range; n=3,6,1,5	0	0	0	0
Urea; below normal range; n=3,6,1,5	0	0	0	0
Urea; above normal range; n=3,6,1,5	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinical Chemistry Results at Baseline

End point title	Part B: Number of Subjects With Abnormal Clinical Chemistry Results at Baseline ^[36]
-----------------	---

End point description:

Clinical chemistry parameters included creatinine, urea, AST, ALT, GGT, ALP, LDH, total bilirubin, albumin, total protein, sodium, potassium, chloride, glucose, and calcium. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'n' signifies number of subjects evaluable for the specified categories. 99999 indicates data was not available as no subjects were evaluable.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects				
ALT; below normal range; n=3,3,4,3,0,4,5,8	0	0	0	0
ALT; above normal range; n=3,3,4,3,0,4,5,8	0	0	0	0
Albumin; below normal range; n=2,3,3,3,1,4,4,8	0	0	0	1
Albumin; above normal range; n=2,3,3,3,1,4,4,8	0	0	0	0
ALP; below normal range; n=2,3,3,3,1,4,4,5	0	0	0	0
ALP; above normal range; n=2,3,3,3,1,4,4,5	0	0	0	0

AST; below normal range; n=3,3,4,3,0,4,5,7	0	0	0	0
AST; above normal range; n=3,3,4,3,0,4,5,7	0	0	0	0
Bilirubin; below normal range; n=3,3,4,3,1,4,4,8	1	0	2	1
Bilirubin; above normal range; n=3,3,4,3,1,4,4,8	0	0	0	0
Calcium; below normal range; n=2,3,2,3,1,4,3,6	0	0	0	0
Calcium; above normal range; n=2,3,2,3,1,4,3,6	0	0	0	0
Chloride; below normal range; n=3,3,4,3,1,4,5,8	1	0	0	0
Chloride; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
Creatinine; below normal range; n=3,3,4,3,1,4,5,8	1	0	2	2
Creatinine; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
GGT; below normal range; n=2,3,4,3,1,4,4,8	0	0	0	0
GGT; above normal range; n=2,3,4,3,1,4,4,8	0	0	0	0
Glucose; below normal range; n=3,3,4,3,1,4,4,8	0	0	0	0
Glucose; above normal range; n=3,3,4,3,1,4,4,8	1	0	3	0
LDH; below normal range; n=0,3,2,3,0,2,2,3	99999	0	0	0
LDH; above normal range; n=0,3,2,3,0,2,2,3	99999	0	0	1
Potassium; below normal range; n=1,3,3,3,0,3,5,7	0	0	0	0
Potassium; above normal range; n=1,3,3,3,0,3,5,7	0	1	0	1
Protein; below normal range; n=3,3,4,3,1,4,4,7	0	0	0	0
Protein; above normal range; n=3,3,4,3,1,4,4,7	0	0	0	0
Sodium; below normal range; n=3,3,4,3,1,4,5,8	1	0	0	0
Sodium; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	1
Urea; below normal range; n=2,3,4,2,1,4,5,8	0	0	1	0
Urea; above normal range; n=2,3,4,2,1,4,5,8	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects				
ALT; below normal range; n=3,3,4,3,0,4,5,8	99999	0	0	0

ALT; above normal range; n=3,3,4,3,0,4,5,8	99999	0	0	3
Albumin; below normal range; n=2,3,3,3,1,4,4,8	0	0	1	0
Albumin; above normal range; n=2,3,3,3,1,4,4,8	0	0	0	1
ALP; below normal range; n=2,3,3,3,1,4,4,5	0	0	0	0
ALP; above normal range; n=2,3,3,3,1,4,4,5	0	0	0	0
AST; below normal range; n=3,3,4,3,0,4,5,7	99999	0	0	0
AST; above normal range; n=3,3,4,3,0,4,5,7	99999	0	0	0
Bilirubin; below normal range; n=3,3,4,3,1,4,4,8	0	0	0	2
Bilirubin; above normal range; n=3,3,4,3,1,4,4,8	0	0	0	0
Calcium; below normal range; n=2,3,2,3,1,4,3,6	0	0	0	1
Calcium; above normal range; n=2,3,2,3,1,4,3,6	0	0	0	1
Chloride; below normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
Chloride; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
Creatinine; below normal range; n=3,3,4,3,1,4,5,8	0	0	1	4
Creatinine; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
GGT; below normal range; n=2,3,4,3,1,4,4,8	0	0	0	0
GGT; above normal range; n=2,3,4,3,1,4,4,8	0	0	0	0
Glucose; below normal range; n=3,3,4,3,1,4,4,8	0	0	0	0
Glucose; above normal range; n=3,3,4,3,1,4,4,8	0	1	0	4
LDH; below normal range; n=0,3,2,3,0,2,2,3	99999	0	0	0
LDH; above normal range; n=0,3,2,3,0,2,2,3	99999	0	0	0
Potassium; below normal range; n=1,3,3,3,0,3,5,7	99999	0	0	0
Potassium; above normal range; n=1,3,3,3,0,3,5,7	99999	0	1	2
Protein; below normal range; n=3,3,4,3,1,4,4,7	0	0	1	2
Protein; above normal range; n=3,3,4,3,1,4,4,7	0	0	0	1
Sodium; below normal range; n=3,3,4,3,1,4,5,8	0	0	0	1
Sodium; above normal range; n=3,3,4,3,1,4,5,8	0	0	0	0
Urea; below normal range; n=2,3,4,2,1,4,5,8	0	0	0	3
Urea; above normal range; n=2,3,4,2,1,4,5,8	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinical Chemistry Results Anytime Between 40 to 48 Hours Post-dose 10

End point title	Part B: Number of Subjects With Abnormal Clinical Chemistry Results Anytime Between 40 to 48 Hours Post-dose 10 ^[37]
-----------------	---

End point description:

Clinical chemistry parameters included creatinine, urea, AST, ALT, GGT, ALP, LDH, total bilirubin, albumin, total protein, sodium, potassium, chloride, glucose, and calcium. Institutional laboratory normal ranges were used. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects				
ALT; below normal range; n=3,3,3,2,0,3,5,6	0	0	0	0
ALT; above normal range; n=3,3,3,2,0,3,5,6	0	0	0	0
Albumin; below normal range; n=3,3,4,2,0,4,4,6	0	0	0	0
Albumin; above normal range; n=3,3,4,2,0,4,4,6	0	0	0	0
ALP; below normal range; n=3,3,3,2,0,4,4,7	0	0	0	0
ALP; above normal range; n=3,3,3,2,0,4,4,7	0	0	1	0
AST; below normal range; n=3,3,2,2,0,2,4,7	0	0	0	0
AST; above normal range; n=3,3,2,2,0,2,4,7	0	0	0	0
Bilirubin; below normal range; n=3,3,4,2,0,4,4,6	1	0	1	0
Bilirubin; above normal range; n=3,3,4,2,0,4,4,6	0	0	0	0
Calcium; below normal range; n=3,3,3,2,0,4,4,7	0	0	0	0
Calcium; above normal range; n=3,3,3,2,0,4,4,7	0	1	1	0
Chloride; below normal range; n=3,3,4,2,0,4,5,8	1	0	0	0
Chloride; above normal range; n=3,3,4,2,0,4,5,8	0	0	0	0
Creatinine; below normal range; n=2,3,4,2,0,4,5,8	1	0	0	1
Creatinine; above normal range; n=2,3,4,2,0,4,5,8	0	0	0	0

GGT; below normal range; n=3,3,4,2,0,4,4,7	0	0	0	0
GGT; above normal range; n=3,3,4,2,0,4,4,7	0	0	0	1
Glucose; below normal range; n=2,3,4,2,0,4,5,8	0	0	0	0
Glucose; above normal range; n=2,3,4,2,0,4,5,8	0	0	0	0
LDH; below normal range; n=2,3,2,1,0,2,3,6	0	0	0	0
LDH; above normal range; n=2,3,2,1,0,2,3,6	0	0	0	0
Potassium; below normal range; n=2,3,2,2,0,2,4,6	0	0	0	0
Potassium; above normal range; n=2,3,2,2,0,2,4,6	0	1	0	1
Protein; below normal range; n=3,3,4,2,0,4,4,7	0	0	0	0
Protein; above normal range; n=3,3,4,2,0,4,4,7	0	0	0	0
Sodium; below normal range; n=3,3,4,2,0,4,5,8	0	0	0	0
Sodium; above normal range; n=3,3,4,2,0,4,5,8	0	0	0	1
Urea; below normal range; n=3,3,4,2,0,4,5,8	1	0	1	1
Urea; above normal range; n=3,3,4,2,0,4,5,8	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[38]	4	5	8
Units: Subjects				
ALT; below normal range; n=3,3,3,2,0,3,5,6		0	0	0
ALT; above normal range; n=3,3,3,2,0,3,5,6		0	0	1
Albumin; below normal range; n=3,3,4,2,0,4,4,6		0	0	1
Albumin; above normal range; n=3,3,4,2,0,4,4,6		0	0	1
ALP; below normal range; n=3,3,3,2,0,4,4,7		0	0	0
ALP; above normal range; n=3,3,3,2,0,4,4,7		0	0	0
AST; below normal range; n=3,3,2,2,0,2,4,7		0	0	0
AST; above normal range; n=3,3,2,2,0,2,4,7		0	0	0
Bilirubin; below normal range; n=3,3,4,2,0,4,4,6		0	0	1
Bilirubin; above normal range; n=3,3,4,2,0,4,4,6		0	0	0
Calcium; below normal range; n=3,3,3,2,0,4,4,7		0	0	0

Calcium; above normal range; n=3,3,3,2,0,4,4,7		1	0	5
Chloride; below normal range; n=3,3,4,2,0,4,5,8		0	0	0
Chloride; above normal range; n=3,3,4,2,0,4,5,8		0	0	0
Creatinine; below normal range; n=2,3,4,2,0,4,5,8		0	1	4
Creatinine; above normal range; n=2,3,4,2,0,4,5,8		0	0	0
GGT; below normal range; n=3,3,4,2,0,4,4,7		0	0	0
GGT; above normal range; n=3,3,4,2,0,4,4,7		0	1	0
Glucose; below normal range; n=2,3,4,2,0,4,5,8		0	0	0
Glucose; above normal range; n=2,3,4,2,0,4,5,8		0	1	1
LDH; below normal range; n=2,3,2,1,0,2,3,6		0	0	0
LDH; above normal range; n=2,3,2,1,0,2,3,6		0	0	1
Potassium; below normal range; n=2,3,2,2,0,2,4,6		0	0	0
Potassium; above normal range; n=2,3,2,2,0,2,4,6		0	1	1
Protein; below normal range; n=3,3,4,2,0,4,4,7		0	1	1
Protein; above normal range; n=3,3,4,2,0,4,4,7		0	0	0
Sodium; below normal range; n=3,3,4,2,0,4,5,8		0	0	0
Sodium; above normal range; n=3,3,4,2,0,4,5,8		0	0	0
Urea; below normal range; n=3,3,4,2,0,4,5,8		0	1	0
Urea; above normal range; n=3,3,4,2,0,4,5,8		0	0	0

Notes:

[38] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Urinalysis Results at Baseline

End point title	Part A: Number of Subjects With Abnormal Urinalysis Results at Baseline ^[39]
-----------------	---

End point description:

Following urine parameters were analysed: epithelial cells (normal range: 0 to 5 cells per high power field [hpf]), erythrocytes (0 to 2 per hpf), granular casts (0 per low power field [lpf]), hyaline casts (0 to 1 per lpf), leukocytes (0 to 5 per hpf), RBC casts (0 per lpf), WBC casts (0 per lpf), waxy casts (0 per lpf) and pH (5 to 8). Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	7	3	6
Units: Subjects				
Epithelial Cells; below normal range; n=2,7,3,6	0	0	0	0
Epithelial Cells; above normal range; n=2,7,3,6	0	0	0	0
Erythrocytes; below normal range; n=2,7,3,6	0	0	0	0
Erythrocytes; above normal range; n=2,7,3,6	0	0	0	0
Granular casts; below normal range; n=2,7,3,6	0	0	0	0
Granular casts; above normal range; n=2,7,3,6	0	0	0	0
Hyaline casts; below normal range; n=2,7,3,6	0	0	0	0
Hyaline casts; above normal range; n=2,7,3,6	0	0	0	0
Leukocytes; below normal range; n=2,7,3,6	0	0	0	0
Leukocytes; above normal range; n=2,7,3,6	0	0	0	0
RBC cast; below normal range; n=2,7,3,6	0	0	0	0
RBC cast; above normal range; n=2,7,3,6	0	0	0	0
WBC cast; below normal range; n=2,7,3,6	0	0	0	0
WBC cast; above normal range; n=2,7,3,6	0	0	0	0
Waxy cast; below normal range; n=2,7,3,6	0	0	0	0
Waxy cast; above normal range; n=2,7,3,6	0	0	0	0
pH; below normal range; n=2,7,3,4	0	0	0	0
pH; above normal range; n=2,7,3,4	0	1	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Urinalysis Results at 48 Hours Post-dose

End point title	Part A: Number of Subjects With Abnormal Urinalysis Results at 48 Hours Post-dose ^[40]
-----------------	---

End point description:

Following urine parameters were analysed: epithelial cells (normal range: 0 to 5 cells per hpf),

erythrocytes (0 to 2 per hpf), granular casts (0 per lpf), hyaline casts (0 to 1 per lpf), leukocytes (0 to 5 per hpf), RBC casts (0 per lpf), WBC casts (0 per lpf), waxy casts (0 per lpf) and pH (5 to 8). Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

48 hours post-dose on Day 1

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	0 ^[41]	6
Units: Subjects				
Epithelial Cells; below normal range; n=3,6,0,6	0	0		0
Epithelial Cells; above normal range; n= 3,6,0,6	0	0		0
Erythrocytes; below normal range; n=3,6,0,6	0	0		0
Erythrocytes; above normal range; n=3,6,0,6	1	0		1
Granular casts; below normal range; n=3,6,0,6	0	0		0
Granular casts; above normal range; n=3,6,0,6	0	0		0
Hyaline casts; below normal range; n=3,6,0,6	0	0		0
Hyaline casts; above normal range; n=3,6,0,6	0	0		0
Leukocytes; below normal range; n=3,6,0,6	0	0		0
Leukocytes; above normal range; n=3,6,0,6	0	0		0
RBC cast; below normal range; n=3,6,0,6	0	0		0
RBC cast; above normal range; n=3,6,0,6	0	0		0
WBC cast; below normal range; n=3,6,0,6	0	0		0
WBC cast; above normal range; n=3,6,0,6	0	0		0
Waxy cast; below normal range; n=3,6,0,6	0	0		0
Waxy cast; above normal range; n=3,6,0,6	0	0		0
pH; below normal range; n=2,6,0,5	0	0		0
pH; above normal range; n=2,6,0,5	0	2		1

Notes:

[41] - No subjects were evaluable

Statistical analyses

Primary: Part B: Number of Subjects With Abnormal Urinalysis Results at Baseline

End point title	Part B: Number of Subjects With Abnormal Urinalysis Results at Baseline ^[42]
-----------------	---

End point description:

Following urine parameters were analysed: epithelial cells (normal range: 0 to 5 cells per hpf), erythrocytes (0 to 2 per hpf), granular casts (0 per lpf), hyaline casts (0 to 1 per lpf), leukocytes (0 to 5 per hpf), RBC casts (0 per lpf), WBC casts (0 per lpf), waxy casts (0 per lpf) and pH (5 to 8). Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	2	2
Units: Subjects				
Epi Cells; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Epi Cells; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Ery; below normal range; n=2,3,2,2,1,2,4,3	0	0	0	0
Ery; above normal range; n=2,3,2,2,1,2,4,3	0	1	1	0
Gran casts; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Gran casts; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Hya casts; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Hya casts; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Leuko; below normal range; n=2,3,2,2,1,2,4,3	0	0	0	0
Leuko; above normal range; n=2,3,2,2,1,2,4,3	0	0	0	0
RBC cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
RBC cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
WBC cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
WBC cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Waxy cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Waxy cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0

pH; below normal range; n=3,3,2,3,1,2,4,5	0	0	0	0
pH; above normal range; n=3,3,2,3,1,2,4,5	0	0	1	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	4	5
Units: Subjects				
Epi Cells; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Epi Cells; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Ery; below normal range; n=2,3,2,2,1,2,4,3	0	0	0	1
Ery; above normal range; n=2,3,2,2,1,2,4,3	0	0	0	0
Gran casts; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Gran casts; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Hya casts; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Hya casts; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Leuko; below normal range; n=2,3,2,2,1,2,4,3	0	0	0	1
Leuko; above normal range; n=2,3,2,2,1,2,4,3	0	1	2	1
RBC cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
RBC cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
WBC cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
WBC cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Waxy cast; below normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
Waxy cast; above normal range; n=2,3,1,2,1,2,2,2	0	0	0	0
pH; below normal range; n=3,3,2,3,1,2,4,5	0	0	0	0
pH; above normal range; n=3,3,2,3,1,2,4,5	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Urinalysis Results Anytime Between 40 to 48 Hours Post-Dose 10

End point title	Part B: Number of Subjects With Abnormal Urinalysis Results Anytime Between 40 to 48 Hours Post-Dose 10 ^[43]
-----------------	--

End point description:

Following urine parameters were analysed: epithelial cells (normal range: 0 to 5 cells per hpf), erythrocytes (0 to 2 per hpf), granular casts (0 per lpf), hyaline casts (0 to 1 per lpf), leukocytes (0 to 5 per hpf), RBC casts (0 per lpf), WBC casts (0 per lpf), waxy casts (0 per lpf) and pH (5 to 8). Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	2	1
Units: Subjects				
Epi Cells; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Epi Cells; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Ery; below normal range; n=2,3,2,1,0,0,3,2	0	0	0	0
Ery; above normal range; n=2,3,2,1,0,0,3,2	0	0	1	0
Gran casts; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Gran casts; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Hya casts; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Hya casts; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Leuko; below normal range; n=2,3,2,1,0,0,3,2	0	0	0	0
Leuko; above normal range; n=2,3,2,1,0,0,3,2	0	0	0	0
RBC cast; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
RBC cast; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
WBC cast; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
WBC cast; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Waxy cast; below normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
Waxy cast; above normal range; n=2,3,1,1,0,0,1,2	0	0	0	0
pH; below normal range; n=2,3,2,1,0,0,3,5	0	0	0	0
pH; above normal range; n=2,3,2,1,0,0,3,5	1	0	1	1

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[44]	0 ^[45]	3	5
Units: Subjects				
Epi Cells; below normal range; n=2,3,1,1,0,0,1,2			0	0
Epi Cells; above normal range; n=2,3,1,1,0,0,1,2			0	0
Ery; below normal range; n=2,3,2,1,0,0,3,2			0	0
Ery; above normal range; n=2,3,2,1,0,0,3,2			2	0
Gran casts; below normal range; n=2,3,1,1,0,0,1,2			0	0
Gran casts; above normal range; n=2,3,1,1,0,0,1,2			0	0
Hya casts; below normal range; n=2,3,1,1,0,0,1,2			0	0
Hya casts; above normal range; n=2,3,1,1,0,0,1,2			0	0
Leuko; below normal range; n=2,3,2,1,0,0,3,2			0	0
Leuko; above normal range; n=2,3,2,1,0,0,3,2			1	0
RBC cast; below normal range; n=2,3,1,1,0,0,1,2			0	0
RBC cast; above normal range; n=2,3,1,1,0,0,1,2			0	0
WBC cast; below normal range; n=2,3,1,1,0,0,1,2			0	0
WBC cast; above normal range; n=2,3,1,1,0,0,1,2			0	0
Waxy cast; below normal range; n=2,3,1,1,0,0,1,2			0	0
Waxy cast; above normal range; n=2,3,1,1,0,0,1,2			0	0
pH; below normal range; n=2,3,2,1,0,0,3,5			0	0
pH; above normal range; n=2,3,2,1,0,0,3,5			0	2

Notes:

[44] - No subjects were evaluable

[45] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Baseline

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Baseline ^[46]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QT interval corrected by Bazett's formula (QTcB) interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[46] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose ^[47]
-----------------	--

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose on Day 1

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 18 to 24 Hours Post-dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 18 to 24 Hours Post-dose ^[48]
-----------------	--

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 18 to 24 hours post-dose on Day 1

Notes:

[48] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Baseline

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Baseline ^[49]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (pre-dose on Day 1)

Notes:

[49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	3
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at 48 Hours Post-dose

End point title	Part A: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at 48 Hours Post-dose ^[50]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

48 hours post-dose on Day 1

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned.

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	2	6
Units: Subjects	0	1	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 1

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 1 ^[51]
-----------------	--

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose 1 on Day 1

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 3

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 3 ^[52]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 3 (Day 2)

Notes:

[52] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 5

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 5 ^[53]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 5 (Day 3)

Notes:

[53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 6

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 4 to 5 Hours Post-Dose 6 ^[54]
-----------------	--

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 4 to 5 hours post-dose 6 (Day 3)

Notes:

[54] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	4	7
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 10

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 10 ^[55]
-----------------	--

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose (Day 5)

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	1	0 ^[56]
Units: Subjects	0	0	0	

Notes:

[56] - No subjects were evaluable

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[57]	3	3	4
Units: Subjects		0	0	0

Notes:

[57] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 8

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation at Pre-dose 8 ^[58]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose 8 (Day 4)

Notes:

[58] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	2	2	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	4	5
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 40 to 48 Hours Post-Dose 10

End point title	Part B: Number of Subjects With Abnormal Clinically Significant Electrocardiogram (ECG) Results per Investigator's Interpretation Anytime Between 40 to 48 Hours Post-Dose 10 ^[59]
-----------------	---

End point description:

A 12-lead ECG was performed for assessment of following ECG parameters: ventricular heart rate, PR interval, QRS interval, QT interval and QTcB interval. Number of subjects with abnormal clinically significant results for any ECG parameter per investigators interpretation are reported in this outcome measure. Safety population included all subjects who received at least 1 dose of IMP. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Anytime between 40 to 48 hours post-dose 10 on Day 5

Notes:

[59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to Part B; hence, only arms for Part B are included.

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Subjects	0	0	0	0

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[60]	4	5	8
Units: Subjects		0	0	0

Notes:

[60] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Time to Maximum Plasma Concentration (tmax)

End point title	Part A: Time to Maximum Plasma Concentration (tmax)
-----------------	---

End point description:

PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Hours				
median (full range (min-max))	4.17 (4 to 4.5)	4.58 (4.42 to 6.18)	7 (4.87 to 48.3)	4.78 (2 to 6.67)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Time to Maximum Plasma Concentration (tmax)

End point title	Part B: Time to Maximum Plasma Concentration (tmax)
-----------------	---

End point description:

PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'n' signifies number of subjects evaluable for the specified categories.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: Hours				
median (full range (min-max))				
Dose 1; n=3,4,3,4,8	4.6 (4.33 to 4.63)	4.32 (3.58 to 11.6)	4.17 (2.5 to 4.17)	4.03 (3.77 to 5.5)
Dose 6; n=3,3,2,3,8	4.43 (4.38 to 4.5)	3.95 (3.67 to 4.88)	4.53 (4.05 to 5)	4.58 (3.58 to 11.5)

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Hours				
median (full range (min-max))				
Dose 1; n=3,4,3,4,8	4.31 (4.08 to 12)			
Dose 6; n=3,3,2,3,8	4.29 (0 to 11.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Maximum Observed Plasma Concentration (Cmax)

End point title	Part A: Maximum Observed Plasma Concentration (Cmax)
-----------------	--

End point description:

PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	6
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	1.59 (± 2.76)	8.08 (± 7.94)	2.98 (± 3.09)	28 (± 17.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Maximum Observed Plasma Concentration (Cmax)

End point title	Part B: Maximum Observed Plasma Concentration (Cmax)
End point description: PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'n' signifies number of subjects evaluable for the specified categories.	
End point type	Secondary
End point timeframe: Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)	

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	3	4
Units: Nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=3,4,3,4,8	43.2 (± 36.7)	24.9 (± 20)	115 (± 182)	39.3 (± 26.4)
Dose 6; n=3,3,2,3,8	30.9 (± 31.3)	67.8 (± 86.3)	212 (± 157)	133 (± 64.8)

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=3,4,3,4,8	56.5 (± 88.1)			
Dose 6; n=3,3,2,3,8	177 (± 151)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Area Under the Plasma Concentration Time Curve From Time Zero to 12 Hours (AUC0-12)

End point title	Part A: Area Under the Plasma Concentration Time Curve From Time Zero to 12 Hours (AUC0-12)
-----------------	---

End point description:

AUC(0 to 12) was calculated using the linear trapezoidal method. No sampling was done at 0 hour. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

0 hour, anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	2	6
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)	9.22 (± 16)	45 (± 48)	6.46 (± 9.14)	201 (± 143)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Area Under the Plasma Concentration Time Curve From Time Zero to 12 Hours (AUC0-12)

End point title	Part B: Area Under the Plasma Concentration Time Curve From Time Zero to 12 Hours (AUC0-12)
-----------------	---

End point description:

AUC(0 to 12) was calculated using the linear trapezoidal method. No sampling was done at 0 hour on Day 1. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified categories. 99999 indicates data could not be calculated due to insufficient number of subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (0 hour, anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	2	1
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=0,0,2,1,4	99999 (± 99999)	99999 (± 99999)	1170 (± 1460)	127 (± 99999)
Dose 6; 1,1,0,1,1	87.9 (± 99999)	184 (± 99999)	99999 (± 99999)	1110 (± 99999)

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	4			
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=0,0,2,1,4	160 (± 120)			
Dose 6; 1,1,0,1,1	1600 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC[0 to t])

End point title	Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC[0 to t])
-----------------	---

End point description:

Area under the plasma concentration-time curve from time 0 to the last measurable concentration was determined using the linear trapezoidal method. No sampling was done at 0 hour. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint. 99999 signifies data could not be calculated due to insufficient subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

0 hour, anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	6	2	6
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)	23.1 (± 99999)	48.1 (± 49.9)	14 (± 1.46)	287 (± 217)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC[0 to t])

End point title	Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC[0 to t])
-----------------	---

End point description:

Area under the plasma concentration-time curve from time 0 to the last measurable concentration was determined using the linear trapezoidal method. No sampling was done at 0 hour on Day 1. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (0 hour, anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	2	4
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=3,4,2,4,8	288 (± 251)	163 (± 132)	1170 (± 1460)	342 (± 240)
Dose 6; n=3,3,2,3,8	225 (± 233)	477 (± 594)	1560 (± 1010)	1310 (± 802)

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)				
Dose 1; n=3,4,2,4,8	315 (± 386)			
Dose 6; n=3,3,2,3,8	1140 (± 845)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Terminal Half-life (t_{1/2})

End point title	Part B: Terminal Half-life (t _{1/2})
-----------------	--

End point description:

T_{1/2} was calculated as loge (2) divided by kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[61]	0 ^[62]	0 ^[63]	0 ^[64]
Units: Hours				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[61] - No subjects were evaluable

[62] - No subjects were evaluable

[63] - No subjects were evaluable

[64] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[65]			
Units: Hours				
arithmetic mean (standard deviation)	()			

Notes:

[65] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Terminal Half-life (t_{1/2})

End point title	Part A: Terminal Half-life (t1/2)
End point description: T1/2 was calculated as loge (2) divided by kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe: Anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1	

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[66]	0 ^[67]	0 ^[68]	5
Units: Hours				
arithmetic mean (standard deviation)	()	()	()	6.22 (± 1.46)

Notes:

[66] - No subjects were evaluable

[67] - No subjects were evaluable

[68] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0 to inf)

End point title	Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0 to inf)
End point description: AUCinf was determined as AUC(0 to t) + (Clast/kel), where Clast was the plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis and kel was the terminal phase rate. No sampling was done at 0 hour. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe: 0 hour, anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1	

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[69]	0 ^[70]	0 ^[71]	5
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)	()	()	()	231 (± 161)

Notes:

[69] - No subjects were evaluable

[70] - No subjects were evaluable

[71] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0 to inf)

End point title	Part B: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0 to inf)
-----------------	---

End point description:

AUCinf was determined as $AUC(0 \text{ to } t) + (C_{\text{last}}/k_{\text{el}})$, where C_{last} was the plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis and k_{el} was the terminal phase rate. No sampling was done at 0 hour on Day 1. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (0 hour, anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[72]	0 ^[73]	0 ^[74]	0 ^[75]
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[72] - No subjects were evaluable

[73] - No subjects were evaluable

[74] - No subjects were evaluable

[75] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[76]			
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)	()			

Notes:

[76] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Trough Concentration at the end of First Dosing Interval (C12)

End point title	Part A: Trough Concentration at the end of First Dosing Interval (C12)
-----------------	--

End point description:

PK Population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 12 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[77]	0 ^[78]	0 ^[79]	0 ^[80]
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[77] - No subjects were evaluable

[78] - No subjects were evaluable

[79] - No subjects were evaluable

[80] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Trough Concentration at the end of First Dosing Interval (C12)

End point title	Part B: Trough Concentration at the end of First Dosing Interval (C12)
-----------------	--

End point description:

PK Population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 12 hours post-dose 6

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	2	3
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	7.6 (± 8.33)	9.55 (± 9.75)	36.9 (± 5.3)	89.8 (± 99.1)

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	124 (\pm 167)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Predicted Plasma Clearance

End point title	Part A: Predicted Plasma Clearance
End point description:	
Clearance was calculated as Dose divided by AUC(0 to inf). PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
Anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1	

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[81]	0 ^[82]	0 ^[83]	5
Units: Liters per hour per kilogram				
arithmetic mean (standard deviation)	()	()	()	12.7 (\pm 7.66)

Notes:

[81] - No subjects were evaluable

[82] - No subjects were evaluable

[83] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Predicted Plasma Clearance

End point title	Part B: Predicted Plasma Clearance
End point description:	
Clearance was calculated as Dose divided by AUC(0 to inf). PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.	
End point type	Secondary

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[84]	0 ^[85]	0 ^[86]	0 ^[87]
Units: Liters per hour per kilogram				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[84] - No subjects were evaluable

[85] - No subjects were evaluable

[86] - No subjects were evaluable

[87] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[88]			
Units: Liters per hour per kilogram				
arithmetic mean (standard deviation)	()			

Notes:

[88] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Apparent Volume of Distribution of the Drug After Extravascular Administration

End point title	Part A: Apparent Volume of Distribution of the Drug After Extravascular Administration
-----------------	--

End point description:

Apparent volume of distribution was estimated as $\text{Dose}/\text{Kel} \times \text{AUC}(0 \text{ to } \infty)$, where Kel=apparent first-order terminal elimination rate constant. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Anytime between 4 to 5 hours, anytime between 6 to 8 hours, 12 hours, 18 to 24 hours and 48 hours post-dose on Day 1

End point values	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg	Cohort 2: RV521 2.0 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[89]	0 ^[90]	0 ^[91]	5
Units: Litres per kilogram				
arithmetic mean (standard deviation)	()	()	()	119 (± 87.4)

Notes:

[89] - No subjects were evaluable

[90] - No subjects were evaluable

[91] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Apparent Volume of Distribution of the Drug After Extravascular Administration

End point title	Part B: Apparent Volume of Distribution of the Drug After Extravascular Administration
-----------------	--

End point description:

Apparent volume of distribution was estimated as $\text{Dose}/\text{Kel} \times \text{AUC}(0 \text{ to } \infty)$, where Kel=apparent first-order terminal elimination rate constant. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[92]	0 ^[93]	0 ^[94]	0 ^[95]
Units: Liters per kilogram				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[92] - No subjects were evaluable

[93] - No subjects were evaluable

[94] - No subjects were evaluable

[95] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[96]			
Units: Liters per kilogram				
arithmetic mean (standard deviation)	()			

Notes:

[96] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Accumulation Ratio

End point title	Part B: Accumulation Ratio
-----------------	----------------------------

End point description:

Accumulation ratio was calculated as ratio of the area under the curve (AUC) during a single dosing interval under steady state conditions to the AUC during a dosing interval after one single dose. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[97]	0 ^[98]	0 ^[99]	0 ^[100]
Units: Ratio				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[97] - No subjects were evaluable

[98] - No subjects were evaluable

[99] - No subjects were evaluable

[100] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[101]			
Units: Ratio				
arithmetic mean (standard deviation)	()			

Notes:

[101] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Percentage Fluctuation

End point title	Part B: Percentage Fluctuation
End point description:	
Percentage fluctuation was calculated as $100 \times (C_{\max} - C_{\min}) / C_{\text{avg}}$, where C_{\min} =minimum plasma concentration and C_{\max} measured over dosing interval. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint. 99999 indicates data could not be calculated due to insufficient number of subjects.	
End point type	Secondary
End point timeframe:	
Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)	

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	0 ^[102]	1
Units: Percentage of fluctuation				
arithmetic mean (standard deviation)	132 (± 99999)	123 (± 99999)	()	8.63 (± 99999)

Notes:

[102] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Percentage of fluctuation				
arithmetic mean (standard deviation)	98.1 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Area Under the Plasma Concentration Time Curve From Time Zero to the end of Last Dosing Interval (AUC0-tau)

End point title	Part B: Area Under the Plasma Concentration Time Curve From Time Zero to the end of Last Dosing Interval (AUC0-tau)
End point description:	
AUC(0 to tau) was determined using the linear trapezoidal method. No sampling was done at 0 hour. PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint. 99999 indicates data could not be calculated due to insufficient number of subjects.	
End point type	Secondary
End point timeframe:	
Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)	

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	0 ^[103]	1
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)	87.9 (± 99999)	184 (± 99999)	()	1110 (± 99999)

Notes:

[103] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Hours*nanogram per milliliter				
arithmetic mean (standard deviation)	1600 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Average Plasma Concentration Over Dosing Interval (Cavg)

End point title	Part B: Average Plasma Concentration Over Dosing Interval (Cavg)
-----------------	--

End point description:

Cavg was estimated as AUC(0 to tau)/tau, where tau=dosing interval (12 hours). PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint. 99999 indicates data could not be calculated due to insufficient number of subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	0 ^[104]	1
Units: Nanogram per milliliter				
arithmetic mean (standard deviation)	7.32 (± 99999)	15.3 (± 99999)	()	92.7 (± 99999)

Notes:

[104] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
------------------	---------------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Nanogram per milliliter				
arithmetic mean (standard deviation)	133 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Minimum Observed Plasma Concentration

End point title	Part B: Minimum Observed Plasma Concentration
-----------------	---

End point description:

PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[105]	0 ^[106]	0 ^[107]	0 ^[108]
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[105] - No subjects were evaluable

[106] - No subjects were evaluable

[107] - No subjects were evaluable

[108] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[109]			
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	()			

Notes:

[109] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Plasma Trough Concentration

End point title	Part B: Plasma Trough Concentration
End point description: PK population included all subjects who received IMP and had at least 1 post-dose PK concentration measurement. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe: Day 1 Dose 1 (anytime between 4 to 5 hours post-dose, 12 hours post-dose), Day 3 Dose 6 (pre-dose, anytime between 4 to 5 hours post-dose, 12 hours post-dose)	

End point values	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[110]	0 ^[111]	0 ^[112]	0 ^[113]
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[110] - No subjects were evaluable

[111] - No subjects were evaluable

[112] - No subjects were evaluable

[113] - No subjects were evaluable

End point values	Cohort 5: RV521 2.5 mg/kg			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[114]			
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)	()			

Notes:

[114] - No subjects were evaluable

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Percent Change From Baseline in Logarithm to Base10 (Log10) Total RSV Viral Load by Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)

End point title	Part B: Percent Change From Baseline in Logarithm to Base10 (Log10) Total RSV Viral Load by Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)
End point description: Percent change from baseline in log10 total RSV viral load was analysed using a mixed effects analysis of covariance (ANCOVA) model. The model was fitted to the subjects treated at the final doses selected for Cohort 5 as pre-planned in statistical analysis plan. Modified Intent to Treat (mITT) population included all subjects who received at least 1 dose of IMP (RV521 or placebo) and had a pre-treatment positive RSV nasopharyngeal swab confirmed by the central laboratory and agreed by the project team during blind data review meeting. Here, 'n' signifies subjects evaluable at the specified timepoints.	
End point type	Secondary
End point timeframe: Baseline (pre-dose on Day 1), 60 hours and 156 hours after first dose on Day 1	

End point values	Cohort 4 and 5 combined: RV521 2.5 mg/kg	Cohort 4 and 5 combined: Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	6		
Units: Percent change				
least squares mean (standard error)				
60 hours; n=5,11	-31.29 (± 8.19)	-23.27 (± 10.48)		
156 hours; n=4,12	-47.53 (± 8.03)	-32.31 (± 11.52)		

Statistical analyses

Statistical analysis title	Placebo versus RV521 2.5 mg/kg
Statistical analysis description:	
Analysis was performed using mixed effects analysis of covariance model on change from baseline in viral load, including a random effect for subject and fixed effects for treatment group, baseline human rhinovirus/enterovirus status (present or absent), visit, visit by treatment group interaction, and baseline viral load as a covariate.	
Comparison groups	Cohort 4 and 5 combined: Placebo v Cohort 4 and 5 combined: RV521 2.5 mg/kg
Number of subjects included in analysis	18
Analysis specification	Pre-specified
Analysis type	other ^[115]
Parameter estimate	Mean difference (net)
Point estimate	-15.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.15
upper limit	9.7

Notes:

[115] - 156 hours

Statistical analysis title	Placebo versus RV521 2.5 mg/kg
Statistical analysis description:	
Analysis was performed using mixed effects analysis of covariance model on change from baseline in viral load, including a random effect for subject and fixed effects for treatment group, baseline human rhinovirus/enterovirus status (present or absent), visit, visit by treatment group interaction, and baseline viral load as a covariate.	
Comparison groups	Cohort 4 and 5 combined: Placebo v Cohort 4 and 5 combined: RV521 2.5 mg/kg

Number of subjects included in analysis	18
Analysis specification	Pre-specified
Analysis type	other ^[116]
Parameter estimate	Mean difference (net)
Point estimate	-8.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.78
upper limit	15.74

Notes:

[116] - 60 hours

Secondary: Part B: Percent Change From Baseline in Logarithm to Base10 (Log10) Total RSV Viral Load by Cell-Based Infectivity Assay (CBIA)

End point title	Part B: Percent Change From Baseline in Logarithm to Base10 (Log10) Total RSV Viral Load by Cell-Based Infectivity Assay (CBIA)
-----------------	---

End point description:

Percent change from baseline in log10 total RSV viral load was analysed using a mixed effects ANCOVA model. The model was fitted to the subjects treated at the final doses selected for Cohort 5 as pre-planned in statistical analysis plan. mITT population included all subjects who received at least 1 dose of IMP (RV521 or placebo) and had a pre-treatment positive RSV nasopharyngeal swab confirmed by the central laboratory and agreed by the project team during blind data review meeting. Here, 'n' signifies subjects evaluable at the specified timepoints.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (pre-dose on Day 1), 60 hours and 156 hours after first dose on Day 1

End point values	Cohort 4 and 5 combined: RV521 2.5 mg/kg	Cohort 4 and 5 combined: Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	6		
Units: Percent change				
least squares mean (standard error)				
60 hours; 5, 11	-54.74 (± 34.87)	-69.56 (± 46.32)		
156 hours; 4, 12	-41.20 (± 34.01)	-10.00 (± 51.88)		

Statistical analyses

Statistical analysis title	Placebo versus RV521 2.5 mg/kg
----------------------------	--------------------------------

Statistical analysis description:

Analysis was performed using mixed effects analysis of covariance model on change from baseline in viral load, including a random effect for subject and fixed effects for treatment group, baseline human rhinovirus/enterovirus status (present or absent), visit, visit by treatment group interaction, and baseline viral load as a covariate.

Comparison groups	Cohort 4 and 5 combined: Placebo v Cohort 4 and 5 combined: RV521 2.5 mg/kg
Number of subjects included in analysis	18
Analysis specification	Pre-specified
Analysis type	other ^[117]
Parameter estimate	Mean difference (net)
Point estimate	-31.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-143.96
upper limit	81.57

Notes:

[117] - 156 hours

Statistical analysis title	Placebo versus RV521 2.5 mg/kg
-----------------------------------	--------------------------------

Statistical analysis description:

Analysis was performed using mixed effects analysis of covariance model on change from baseline in viral load, including a random effect for subject and fixed effects for treatment group, baseline human rhinovirus/enterovirus status (present or absent), visit, visit by treatment group interaction, and baseline viral load as a covariate.

Comparison groups	Cohort 4 and 5 combined: Placebo v Cohort 4 and 5 combined: RV521 2.5 mg/kg
Number of subjects included in analysis	18
Analysis specification	Pre-specified
Analysis type	other ^[118]
Parameter estimate	Mean difference (net)
Point estimate	14.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-91.68
upper limit	121.33

Notes:

[118] - 60 hours

Secondary: Part B: Time to Resolution of RSV-Related Signs and Symptoms

End point title	Part B: Time to Resolution of RSV-Related Signs and Symptoms
-----------------	--

End point description:

Time to resolution was calculated for RSV-related signs and symptoms that were present at study start and was defined as the time of randomisation to the time that RSV-related signs and symptoms were absent. mITT population included all subjects who received at least 1 dose of IMP (RV521 or placebo) and had a pre-treatment positive RSV nasopharyngeal swab confirmed by the central laboratory and agreed by the project team during blind data review meeting. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 13 days

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Days				
median (full range (min-max))	6.20 (6.1 to 6.6)	6.20 (6.2 to 6.3)	6.45 (5.9 to 6.8)	3.80 (2.6 to 5.0)

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Days				
median (full range (min-max))	4.90 (4.9 to 4.9)	6.30 (4.6 to 6.9)	6.00 (2.5 to 6.7)	6.10 (4.1 to 6.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: Time to Improvement in RSV-Related Signs and Symptoms

End point title	Part B: Time to Improvement in RSV-Related Signs and Symptoms
-----------------	---

End point description:

Time to improvement was calculated for RSV-related signs and symptoms that were classified as moderate or severe during the course of the study and was defined as the time from randomisation to the time that RSV-related signs and symptoms were mild or absent. mITT population included all subjects who received at least 1 dose of IMP (RV521 or placebo) and had a pre-treatment positive RSV nasopharyngeal swab confirmed by the central laboratory and agreed by the project team during blind data review meeting. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 13 days

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	3	4	2
Units: Days				
median (full range (min-max))	2.25 (1.5 to 3.0)	0.50 (0.5 to 6.3)	3.15 (2.1 to 5.9)	2.55 (1.1 to 4.0)

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Days				
median (full range (min-max))	1.90 (1.9 to 1.9)	4.35 (3.6 to 6.9)	3.00 (1.0 to 6.0)	6.00 (1.5 to 6.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Part B: RSV Clinical Scoring System Scores

End point title	Part B: RSV Clinical Scoring System Scores
-----------------	--

End point description:

RSV clinical score was a composite score for infants with RSV infection ≥ 1 month of age based on 4 items (respiratory rate, wheezing, retraction of respiratory muscles and general condition). Score for each item ranged from 0 to 3 where 0=none/normal and 3=severe. Total score was calculated as sum of individual items and ranged from 0 to 12, where higher score indicated severe disease. RSV symptoms were graded as mild: score ≤ 5 , moderate: score > 5 but < 9 and severe: score ≥ 9 . mITT population was analysed. Here, 'Number of Subjects Analysed' signifies subjects evaluable for this endpoint and 'n' signifies subjects evaluable at the specified timepoints. 99999 signifies data could not be calculated due to insufficient subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (pre-dose 1 on Day 1), pre-dose 3, pre-dose 5, pre-dose 7, pre-dose 9, anytime between 40 to 48 hours post-dose 10 on Day 5

End point values	Cohort 3: Placebo	Cohort 3: RSV1 2.5 mg/kg	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	4	2
Units: Units on a scale				
arithmetic mean (standard deviation)				
Baseline; n=2,3,4,2,1,4,5,8	3.5 (\pm 2.12)	5.0 (\pm 1.73)	6.8 (\pm 2.50)	4.5 (\pm 6.36)
pre-dose 3; n=3,3,4,2,1,4,5,8	2.0 (\pm 1.73)	4.0 (\pm 2.65)	2.5 (\pm 1.29)	1.0 (\pm 1.41)
pre-dose 5; n=3,3,4,2,1,4,5,8	1.0 (\pm 1.00)	2.7 (\pm 2.08)	1.8 (\pm 1.50)	2.5 (\pm 3.54)
pre-dose 7; n=3,3,4,2,1,3,5,8	0.7 (\pm 0.58)	3.0 (\pm 1.73)	1.3 (\pm 1.50)	2.5 (\pm 3.54)
pre-dose 9; n=1,2,2,1,1,2,4,4	0.0 (\pm 99999)	3.5 (\pm 2.12)	1.5 (\pm 0.71)	1.0 (\pm 99999)
40 to 48 hours post-dose 10; n=3,3,4,2,0,3,5,8	0.3 (\pm 0.58)	1.0 (\pm 1.00)	0.5 (\pm 0.58)	0.0 (\pm 0.00)

End point values	Cohort 4: Placebo	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 5: RV521 2.5 mg/kg
------------------	----------------------	---------------------------------	----------------------	---------------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	4	5	8
Units: Units on a scale				
arithmetic mean (standard deviation)				
Baseline; n=2,3,4,2,1,4,5,8	8.0 (± 99999)	6.8 (± 2.22)	6.2 (± 3.56)	6.0 (± 2.73)
pre-dose 3; n=3,3,4,2,1,4,5,8	4.0 (± 99999)	5.0 (± 0.00)	1.8 (± 1.10)	4.3 (± 2.38)
pre-dose 5; n=3,3,4,2,1,4,5,8	3.0 (± 99999)	3.3 (± 0.96)	1.4 (± 1.14)	3.9 (± 2.75)
pre-dose 7; n=3,3,4,2,1,3,5,8	1.0 (± 99999)	1.3 (± 0.58)	1.6 (± 0.55)	2.3 (± 2.12)
pre-dose 9; n=1,2,2,1,1,2,4,4	1.0 (± 99999)	2.0 (± 1.41)	1.8 (± 0.50)	2.3 (± 0.96)
40 to 48 hours post-dose 10; n=3,3,4,2,0,3,5,8	99999 (± 99999)	1.0 (± 1.00)	1.2 (± 1.10)	0.6 (± 0.52)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of IMP on Day 1 up to Day 7 for Part A; From start of IMP on Day 1 up to Day 12 for Part B

Adverse event reporting additional description:

Same event may appear as SAE and non-SAE, what is presented are distinct events. Event may be categorised as serious in 1 subject and as non-serious in another or 1 subject may have experienced both serious and non-serious event during study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Cohort 1: RV521 1.0 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 1.0 milligram per kilogram (mg/kg) of RV521 orally on Day 1.

Reporting group title	Cohort 1: RV521 2.0 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.0 mg/kg of RV521 orally on Day 1.

Reporting group title	Cohort 1: RV521 2.5 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received a single dose of 2.5 mg/kg of RV521 orally on Day 1.

Reporting group title	Cohort 2: RV521 2.0 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received a single dose of 2 mg/kg of RV521 orally on Day 1.

Reporting group title	Cohort 3: Placebo
-----------------------	-------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 5: RV521 2.5 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 3: RV521 3.5 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 3.5 mg/kg every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 3: RV521 5 mg/kg
-----------------------	-------------------------

Reporting group description:

Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 5 mg/kg every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 4: Placebo
-----------------------	-------------------

Reporting group description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 4: RV521 2.5 mg/kg
-----------------------	---------------------------

Reporting group description:

Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.

Reporting group title	Cohort 5: Placebo
Reporting group description: Infants aged ≥ 1 month to < 6 months hospitalised with RSV LRTI received placebo every 12 hours (BID) orally for 5 days.	
Reporting group title	Cohort 3: RSV1 2.5 mg/kg
Reporting group description: Infants aged ≥ 6 months to ≤ 36 months hospitalised with RSV LRTI received RV521 2.5 mg/kg every 12 hours (BID) orally for 5 days.	

Serious adverse events	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 2: RV521 2.0 mg/kg	Cohort 3: Placebo	Cohort 5: RV521 2.5 mg/kg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	
General disorders and administration site conditions			

Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 3: RSV1 2.5 mg/kg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Cohort 1: RV521 1.0 mg/kg	Cohort 1: RV521 2.0 mg/kg	Cohort 1: RV521 2.5 mg/kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	4 / 7 (57.14%)	3 / 3 (100.00%)
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Withdrawal syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cyanosis central			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Irritability			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Bacterial test positive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus arrhythmia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Bradycardia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Blood and lymphatic system disorders Thrombocytosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Ear and labyrinth disorders Otorrhoea subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders Post-tussive vomiting subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 3 (33.33%) 1
Anal erythema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	3 / 3 (100.00%) 4
Abdominal distension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0

Renal and urinary disorders Oliguria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Infections and infestations Croup infectious subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Bacterial disease carrier subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders Hypernatraemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Metabolic acidosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0

Non-serious adverse events	Cohort 2: RV521 2.0 mg/kg	Cohort 3: Placebo	Cohort 5: RV521 2.5 mg/kg
Total subjects affected by non-serious adverse events subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	1 / 8 (12.50%)
Vascular disorders Phlebitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
General disorders and administration site conditions			

Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Withdrawal syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cyanosis central			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Irritability			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Investigations			
Bacterial test positive			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Transaminases increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Cardiac disorders			
Sinus arrhythmia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Blood and lymphatic system disorders			
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Ear and labyrinth disorders			
Otorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Gastrointestinal disorders			
Post-tussive vomiting subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Anal erythema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0

Abdominal distension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Renal and urinary disorders Oliguria subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Infections and infestations Croup infectious subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1
Bacterial disease carrier subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0
Metabolism and nutrition disorders Hypernatraemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	0 / 8 (0.00%) 0
Metabolic acidosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	0 / 8 (0.00%) 0

Non-serious adverse events	Cohort 3: RV521 3.5 mg/kg	Cohort 3: RV521 5 mg/kg	Cohort 4: Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	1 / 1 (100.00%)
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Withdrawal syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cyanosis central			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Irritability			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Investigations			

Bacterial test positive subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Monocyte count decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Transaminases increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Cardiac disorders Sinus arrhythmia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Blood and lymphatic system disorders Thrombocytosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Ear and labyrinth disorders Otorrhoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Gastrointestinal disorders Post-tussive vomiting subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0

Diarrhoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Anal erythema subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1	1 / 1 (100.00%) 1
Abdominal distension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	1 / 1 (100.00%) 1
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Renal and urinary disorders Oliguria subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	1 / 1 (100.00%) 1
Infections and infestations Croup infectious subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Bacterial disease carrier			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 1 (0.00%) 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Cohort 4: RV521 2.5 mg/kg	Cohort 5: Placebo	Cohort 3: RSV1 2.5 mg/kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	3 / 5 (60.00%)	2 / 3 (66.67%)
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Withdrawal syndrome			
subjects affected / exposed	2 / 4 (50.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Catheter site inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Cyanosis central			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Increased bronchial secretion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Psychiatric disorders Irritability subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Investigations Bacterial test positive subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Monocyte count decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1
Transaminases increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1
Cardiac disorders Sinus arrhythmia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Bradycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Blood and lymphatic system disorders Thrombocytosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1
Leukocytosis			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1
Ear and labyrinth disorders Otorrhoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders Post-tussive vomiting subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Anal erythema subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all) Abdominal distension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0 1 / 4 (25.00%) 1 0 / 4 (0.00%) 0 1 / 4 (25.00%) 1 0 / 4 (0.00%) 0	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0	1 / 3 (33.33%) 1 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 2 / 3 (66.67%) 2 0 / 3 (0.00%) 0
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) Rash macular subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0 1 / 4 (25.00%) 1	1 / 5 (20.00%) 1 0 / 5 (0.00%) 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0
Renal and urinary disorders Oliguria subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Infections and infestations Croup infectious subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2	0 / 3 (0.00%) 0

Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Bacterial disease carrier subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Hypernatraemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Metabolic acidosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 May 2019	Inclusion of optional Study Part C. Change in dosage form to dry powder blend requiring dispersal in water prior to administration and inclusion of text concerning information provided to parents/carers as to how to prepare and record administration of IMP at home. Adjustment of minimum hospital stay to at least 3 days. Adjustment to RSV signs and symptoms to be monitored and how these will be analysed. Update to permitted concomitant medications. Update to assessments to include evaluation of hydration status. Clarification of duration of SAE reporting and SUSAR reporting commitment.
15 January 2020	Addition of central laboratory (ECG analysis). Addition of respiratory pathogen screen of baseline nasopharyngeal swabs using BioFire assay.
01 March 2021	Change to central laboratory responsible for viral resistance emergence testing. Reduction in nasopharyngeal swab sampling timepoints and rationalisation of PK sampling. Clarification of subject replacement parameters in all study parts. Update to study analysis populations and their definitions.
31 January 2022	Amendment to Part C study design, objectives, and endpoints. Clarification of requirements for opening Cohort 5. Clarification of informed consent requirements in line with local regulations. Adjustment to inclusion and exclusion criteria. Amendment to Part C duration of hospitalisation. Revision of stopping criteria, correction of adverse reaction definition, clarification of AE severity grading and AE Part C follow-up duration in response to regulatory request. Amendment to prior and concomitant medication section to clarify permitted medications/therapy and update to list of drugs affecting CYP3A4 and P-gp. Introduction of ReSVinet Scale for Clinicians in Part C. Clarification of study procedures and permitted time windows. Clarification of information to be provided to the parent/carer at discharge. Clarification of local laboratory and central laboratory safety testing. Updated monitoring section to reflect changes in monitoring during COVID-19 pandemic.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported